Significant weight gain benefits of nanocrystalline megestrol acetate for patients with cancer anorexia-cachexia syndrome
MA-ES administered at 625 mg/day for over three cycles may offer superior weight gain benefits compared to the conventional MA tablets at 800 mg/day in hormone-insensitive patients with CACS. Moreover, MA-ES appears to provide more significant advantages in improving appetite and overall quality of life. Therefore, MA-ES may offer better clinical benefits compared to MA tablets for CACS patients.
Authors
- Chengsong Cao (ORCID: https://orcid.org/0000-0002-5243-2919)
- Cheng Xue (ORCID: https://orcid.org/0000-0002-4132-9406)
- Yong Liu (ORCID: https://orcid.org/0000-0001-5102-0309)
- Qing Li (ORCID: https://orcid.org/0000-0002-4982-1024)
- Xin Jin (ORCID: https://orcid.org/0000-0001-9813-547X)
- Kang Pan (ORCID: https://orcid.org/0000-0003-4070-2974)
Institutions
- Xuzhou Medical College (CN)
Publication Details
- Journal
- Translational Cancer Research
- Published
- 2025-05-01
- DOI
- https://doi.org/10.21037/tcr-2025-866
- Primary Topic
- Nutrition and Health in Aging
- Type
- article
- Field-Weighted Citation Impact
- 0.00